MSAA Recognizes Ten Years of Artwork from Individuals with Multiple Sclerosis
May 10, 2019
Personalized Combination Therapies Yield Better Cancer Outcomes
May 13, 2019
Show all

Study Eyes Physical, Mental Differences Between Children with MS, ADS

Comparing children with MS to those with acute demyelinating syndromes (ADS) highlights the implications of fatigue, depression, and quality of life.

Retrospective comparison between children with multiple sclerosis (MS) and those with related acute demyelinating syndromes (ADS) highlights the implications of fatigue, depression, and quality of life in these patients.

Those are the findings from a study, “Fatigue, depression, and quality of life in children with multiple sclerosis: a comparative study with other demyelinating diseases” published in the journal Developmental Medicine & Child Neurology.

Demyelinating disorders include any condition that results in damaged myelin (the protective coat of neurons), ultimately leading to the formation of scar tissue and malfunctioning nerve signaling. ADS gathers different diseases in children, and can develop into either monophasic (only one occurrence of demyelination) or multiphasic diseases (chronic demyelination).

MS is the most common type of chronic multiphasic demyelination disease, and studies have associated the condition with cognitive dysfunction, mental conditions, and poor quality of life (QoL), apart from neurological symptoms.

However, few studies have compared fatigue and depression levels between children with MS and ADS. This study retrospectively analyzed and compared those parameters between the two groups, and also evaluated self-reported and parent-reported evaluations about QoL.

The comparative study analyzed the physical and mental functions of children followed in the National Referral Centre of rare inflammatory brain and spinal diseases at the University Hospital of Paris-Sud, France. Researchers assessed 26 children with MS (mean age 15.2 years) and 11 children with ADS (mean age 11.7 years), with follow-up times of 33.6 and 20.3 months, respectively.

ADS included disease-like relapsing myelin oligodendrocyte glycoprotein (MOG, four patients), acute demyelinating encephalomyelitis (three patients), and other clinically isolated syndrome diagnoses (four patients).

Researchers evaluated the level of disability, fatigue, depression, and QoL of the patients based on established clinical scales used in MS patient assessment. The Expanded Disability Status Scale (EDSS) — an assessment tool for MS, with higher scores indicating increased disability — was used to measure impairment.

Read on: Study Eyes Physical, Mental Differences Between Children with MS, ADS

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.